Press Release
GLP-1 Boom Reshapes the Global Autoinjectors Market as Obesity and Diabetes Therapies Drive Device Demand
FOR IMMEDIATE RELEASE | Global Data Route Analytics | September 2026
Endocrinology, metabolic and hormonal disorders are the fastest-growing therapy area in the Global Autoinjectors Market at a 14.29% CAGR, reaching USD 11,116.53 Million by 2035, as GLP-1 and dual GIP/GLP-1 therapies convert into unprecedented device volumes.
The GLP-1 era has changed the economics of the autoinjector. According to Global Autoinjectors Market Size, Share, Trends & Forecast 2020–2035, published by Global Data Route Analytics, the endocrinology, metabolic and hormonal disorders therapy area, home to type 1 and type 2 diabetes, obesity and chronic weight management, severe hypoglycaemia rescue and growth-hormone therapy, will grow at a 14.29% CAGR to USD 11,116.53 Million by 2035, the fastest of the twelve therapy areas the report quantifies. The overall market rises from USD 13,451.97 Million in 2025 to USD 48,029.60 Million by 2035 at 13.57%.
The demand base is structural. The IDF Diabetes Atlas (11th edition) counts 589 million adults living with diabetes today, projected to reach 852.5 million by 2050, with China, India and Indonesia alone accounting for 50.5% of the world's undiagnosed cases. Obesity has become a treated chronic condition rather than a lifestyle diagnosis, and once-weekly injectable peptides are the therapy of choice.
|
Get the sample report with segment-level data tables and the full table of contents:
|
Device Supply Became the Constraint
The report documents how the multi-year US shortages of semaglutide and tirzepatide were resolved only once manufacturers demonstrated national-scale capacity, and how the FDA's own communications identified device fill-finish and assembly, not molecule synthesis, as the limiting step. WHO's 2025 addition of GLP-1 receptor agonists to its Essential Medicines List extends that demand to health systems worldwide.
Manufacturers responded with historic capital deployment. Novo Nordisk's capital expenditure reached DKK 60.1 billion in 2025; BD committed USD 110 million to expand glass prefillable-syringe production in Nebraska; Ypsomed grew commercial autoinjector sales 33.6% while building toward one billion devices of installed annual capacity; SHL Medical opened a USD 220 million, 360,000 sq ft facility in South Carolina and announced Quanta, a multi-fixed-dose platform for once-weekly cardiometabolic therapies; and Nemera expanded GLP-1 device production in Szczecin, Poland.
What the Numbers Show
- Therapeutic peptides, proteins and polypeptides, the modality class containing insulin, GLP-1 and dual GIP/GLP-1 agonists, is quantified separately from monoclonal antibodies, small molecules and antisense oligonucleotides.
- Over 1.0–2.25 mL and over 2.25 mL container capacities grow at 14.02% and 14.67% CAGR respectively, faster than the up-to-1.0 mL category, as higher-dose metabolic presentations enter the market.
- Home and self-care is the dominant end-use setting, reaching USD 33,752.72 Million by 2035 at a 13.89% CAGR.
- Asia-Pacific is the fastest-growing region at 14.12% CAGR, with Ypsomed's Changzhou plant and CHF 205.6 million capacity programme signalling localisation.
|
Need country-level, segment-level or company-specific data? Our analysts respond within one business day:
|
Pricing and Counterfeit Pressure
Growth is not friction-free. CMS negotiated a 2027 Medicare price of USD 274 per month for Ozempic against a USD 959 list price, a 71% gap on the same device, and the report's dedicated price-analysis chapter compares injectable and oral GLP-1 pricing across list, net, acquisition, negotiated and cash channels. The FDA has also seized thousands of counterfeit GLP-1 pens inside the legitimate US supply chain, turning device-level serialisation and authentication into a market requirement.
Companies Profiled in the GLP-1 and Metabolic Chapter
A dedicated chapter profiles diabetes, GLP-1 and metabolic drug-delivery companies including West Pharmaceutical Services, MannKind, Dexcom, Medtronic Diabetes, Nemera, Datwyler, Biocon Biologics, Wockhardt, SHL Medical and Innovent Biologics, alongside pharma platform users Novo Nordisk, Eli Lilly, Sanofi and AstraZeneca and the primary-container suppliers BD, SCHOTT Pharma, Nipro and Terumo.
|
Buy the full report at a special introductory price:
|
About the Report
The 1,750-page study quantifies the Global Autoinjectors Market across twelve segmentation axes, five regions and 31 countries, includes a dedicated ten-dimension price-analysis chapter and profiles 151 companies across 15 chapters covering device manufacturers, platform and injection-technology companies, pharma users, biosimilar and specialty-injectable companies, connected-device, CDMO, primary-container, safety-syringe, automation and regional emerging-market companies. Deliverables include a 700+ table PDF and an Excel data pack with verified company and product links.
About Global Data Route Analytics
Global Data Route Analytics is a market research and consulting firm delivering syndicated and custom research across healthcare, life sciences, medical devices and adjacent industries. Our reports combine primary interviews, verified secondary sources and proprietary estimation models to give manufacturers, investors and policy teams a quantified basis for decisions.
Report: Global Autoinjectors Market Size, Share, Trends & Forecast 2020–2035
Media & Sales Contact: Global Data Route Analytics | globaldatarouteanalytics.com/contact